Cipla Ltd share Price Today

Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms.

• Indian branded formulations business accounts for ~45% of revenues and major therapies include respiratory, anti-infectives, gastro-intestinal among others

• Cipla derives 26% of its export revenues from the US followed by 10% from South Africa, 17% from RoW markets and 2% from APIs

Cipla reported a mixed set of numbers wherein US sales and gross profit margins were above I-direct estimates but missed on the India front due to Covid base adjustment.

• Revenue grew 9.1% YoY to ₹ 5,739 crore

• EBITDA margins increased 620 bps YoY to 20.5%

• Adjusted PAT increased 59.3% YoY to ~₹ 654 crore

Pharmaceuticals firm Cipla announced Q3FY24 result:

Financial Highlights:

• Income from Operations: Rs 6,544 crore, representing a 14.2% YoY increase.

• EBITDA: Rs 1,720 crore, translating to 26.3% of Income from Operations, reflecting a 24.9% YoY growth.

• Profit After Tax (PAT): Rs 1,049 crore, marking a substantial increase of 32.7% YoY.

Business Performance by Region:

• One-India: Revenue growth stood at 12% YoY, bolstered by Branded Prescription, Trade Generics, and Consumer Health verticals. The market share for chronic therapy increased by 115 bps YoY to 60.3%.
• North America: Recorded highest ever quarterly revenue at $230 Mn, an 18% YoY growth, driven by volume traction in key assets such as Lanreotide and Albuterol, along with strong base business demand.
• South Africa: Demonstrated a 15% growth in local currency terms YoY, fueled by strong performance across prescription, OTC, and tender segments.

Research and Development (R&D):

• Investment: R&D investments were reported at Rs 400 crore or 6.1% of sales, showcasing an increase of 10% YoY.

Balance Sheet Health:

• Robust Net Cash Position: Rs 7,143 crore post the repayment of ZAR 720 Mn term loan in South Africa.

Umang Vohra, MD and Global CEO of Cipla Ltd, stated: "I am happy to announce results for yet another quarter which further established our strengths of our core business in India, North America, and South Africa. Our topline growth for the quarter was at an impressive 14% YoY with strong EBITDA margins at 26.3%. One India business grew at a healthy 12% YoY backed by strong performance across Branded Prescroreiption, Trade Generics and Consumer Health. In North America, we continue to scale newer peaks by posting the highest ever quarterly revenue yet again at $ 230 Mn, supported by positive traction in key assets and base business. Our South Africa business further extended its momentum from last quarter by growing at 15% in local currency terms driven by strong execution across prescription, OTC, and tender. Our focus continues on expansion in chronic therapies, growing big brands, global wellness as well as developing our R&D pipeline in respiratory and peptides. We will continue to focus on driving profitable growth across businesses".

Result PDF